Tagged with Strategy,

China Hong Chow, general manager of Roche Pharma China, shares Roche China’s incredible milestones over the past few years, including four pivotal oncology drugs listed on the National Reimbursement Drug List (NRDL) in 2017; the company’s USD 129 million investment in a new innovation center in Shanghai, the third strategic innovation…

China This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. We start in China, where the heads of Merck, Ipsen, Chiesi, Gedeon Richter and AbbVie’s Chinese affiliates give their…

France Abbvie France’s Pierre-Claude Fumoleau outlines his strategic priorities for the affiliate, AbbVie’s unique corporate culture and ethos, and how he envisions upcoming regulatory reforms playing out in France.   We are still a very young company… and that means that we are still very much in the process of constructing…

Korea SK Group, the second largest conglomerate in South Korea and renowned as a leader in energy, telecommunications, and the semiconductor business, entered drug development in 1993. In an exclusive interview, Jeong Woo Cho PhD, CEO & president of SK Biopharmaceuticals and SK Life Science, provides an overview of the current…

Korea Bong Gil Nam, chairman and owner of Pharmbio Korea, offers his insights on his company’s importance in differentiating itself from the generic competitors in the market. Mr Nam also explains his strategy to expand into the East Asian market and provides his assessment on how established Korean pharmaceutical companies can…

France Emmanuelle Quilès, CEO of Janssen France, speaks about how she joined the American multinational with the ambition to bring digitalization and transform the organization from the inside. Quilès goes on to cover the operational specifics of the affiliate and shares her insights on the French pharma ecosystem.   When I…

Korea Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean patients by utilising legislation regarding orphan drugs to fast track the market entry of their products. Yoshii also provides his assessment of how low drug pricing is indirectly affecting the decisions of Mitsubishi…

Spain Staffan Schüberg, CEO of Esteve, highlights the restructure of the company as it moves towards its new age of being a truly innovative pharmaceutical company on a global level. Furthermore, he highlights the international strategy and the role the US market will play in the future, as well as his…

France Thierry Hulot, president biopharma of Merck France, explains how France has become more open to diversity, while still needing significant reforms in the healthcare sector to remain competitive. He also shares insights into his career and the learnings from the Levothyrox case.   Overall, we are a very important branch…

Spain Marieta Jiménez, president and general manager of Merck Spain, highlights her three top priorities: innovation, science and technology, and women’s equality. Furthermore, she gives an overview of the need for better collaboration for long-term sustainably of the Spanish healthcare system and breaks down the role of the ClosingGap cluster to…

France Pascal Joly, general manager of Medac France, explains how he and his executive team have built the French affiliate from scratch, while highlighting the importance of gaining swift market access and having a diverse product portfolio.   Lyon carries a number of strategic advantages: economically speaking, office spaces are significantly…

France Philippe Truelle, President of CDM Lavoisier, highlights the financial impact of the EU’s Falsified Medicines Directive (FMD) on SMEs across Europe and explains how France is becoming increasingly attractive to foreign investors under the Macron Presidency. He also speaks out about CDM Lavoisier’s longstanding legacy in France and outlines the…